Short Term Outcomes of Low Dose Liraglutide in Obese Non Diabetic Indian Subjects-A Real World Experience

Chaudhuri, Soumyabrata Roy

doi:10.23880/doij-16000140

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[17] Significant reduction of mean body weight (from 96.33 ± 14.45 at baseline to 90 ± 13.47 at 3 months and to 86.25 ± 13.19 at 9 months, P < 0.001), BMI (from 34.99 ± 5.66 at baseline to 32.66 ± 5.17 at 3 months to 31.29 ± 4.97 at 9 months, P < 0.001), and waist circumference (from 93.33 ± 5.43 at baseline to 90.33 ± 5.09 at 3 months to 88.5 ± 4.59 at 9 months, P < 0.001) were reported after 3 and 9 months of liraglutide treatment, with a dose of 1.8 mg (Roy et al 2016). [16] Even a low dose (0.6 mg) of liraglutide showed a reduction of 6.03 kg over 24 weeks. Hence, in the scanty Indian data available, liraglutide at a dose much lower than that of 3 mg (as the approved anti-obesity dose) produced a substantial reduction in body weight of obese non-diabetic Indian subjects, which can make it a relatively less expensive anti-obesity agent in days to come.…”

Section: Discussionmentioning

confidence: 99%

“…Ten observational studies have recently been published with liraglutide in a real-world setting (Jothydev et al , Kaur et al , Sanyal et al , Roy Chaudhri et al , Wagnoo et al , Verma et al , and Majumder et al ), from various parts of India. [10111213141516171819] We are presenting a review of the real-world experience with liraglutide in India.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Liraglutide – Indian experience

Majumder

Soumyabrata

Sanyal

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

Liraglutide is an effective drug for the treatment of type 2 diabetes mellitus (T2DM). The aim of this review is to collate evidence on the real-world clinical effectiveness of liraglutide from the published Indian studies. A review of publications was conducted to identify observational studies that assessed the effectiveness of liraglutide among Indian T2DM. Total ten publications were retrieved and these observational studies are compared with the results of the liraglutide randomized controlled trial (RCT) program (Liraglutide Effect and Action in Diabetes [LEAD]). Liraglutide therapy demonstrated HbA1c reduction in the Indian population up to 2.26% and 2.54%, over 24 and 52 weeks, respectively. Among the LEAD trials, the HbA1c reduction at 24 weeks was maximum in LEAD-4 with 1.5% reduction at both doses used (1.2 and 1.8 mg) and up to 1.14% in LEAD-3 with a dose of 1.8 mg. The weight loss among Indian subjects was generally around 5 kg or more with maximum weight loss of 8.6 kg over 24 weeks. The maximal weight loss in LEAD studies was less than 3 kg with an exception of 3.24 kg in LEAD-6. In over 52 weeks of liraglutide therapy among Indian subjects, mean weight loss was 7.4 kg, which was 3.5 times more than of LEAD program. Two Indian observational studies also demonstrated significant weight loss among nondiabetic obese subjects at a much lower than that of 3 mg anti-obesity dose. Gastrointestinal (GI) events are the commonly reported adverse events with Indian studies as well as LEAD program. Liraglutide therapy produces better glycemic control and more weight loss among Indian T2DM subjects compared with RCTs conducted in western population with almost similar adverse consequences.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Liraglutide – Indian experience

Majumder

Soumyabrata

Sanyal

et al. 2018

Indian J Endocr Metab

View full text Add to dashboard Cite

show abstract

“…Glucagon-like peptide-1 (GLP-1) agonists act at GLP-1 receptors in pancreatic beta cells to increase glucose-dependent insulin secretion, in pancreatic alpha cells to decrease glucagon release and slow gastric emptying. Over the years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become integral in diabetes management as demonstrated by various publications from India [1][2][3][4][5][6][7]. Short-acting GLP-1 RAs requires either a once-daily (e.g.…”

Section: Introductionmentioning

confidence: 99%

First Fabulous Fifty – An Initial Experience of Dulaglutide from a Tertiary Care Centre in Eastern India

2018

Endocrinol Diabetes Metab J

View full text Add to dashboard Cite

Objective: This retrospective single centred real world observational study was undertaken with the aim to introspect the glycaemic control, weight loss, changes in lipid parameters, adverse events and treatment adherence with Dulaglutide therapy. Methodology: Single centered, retrospective, real world, observational study conducted on subjects taking liraglutide for a mean duration of 41 weeks in the endocrine outpatient department. Results: Data of 45 subjects were available. Mean age was 46.67 ± 5.53years. Glycosylated haemoglobin (HbA1c) significantly decreased from 8.68 ± 0.43% at baseline to 7.58 ± 0.19% at end of therapy. Body weight significantly reduced from 74.2 ± 8.07 kg at baseline to 69.27 ± 4.74kg at end of therapy and BMI significantly declined from 33.06 ± 4.5 to 30.09 ± 0.93 at end of therapy respectively. Nausea, vomiting and diarrhoea (15.55%) were the major adverse events noted in the study. Only one patient developed acute pancreatitis (2.22%). Conclusion: Treatment with Dulaglutide resulted in clinically meaningful HbA1c, FPG and weight reductions. The overall safety profile is consistent with the GLP-1 receptor agonist class. However, Dulaglutide did not show statistically greater reduction of glycaemic parameters in the subset of Indian patients compared to RCT data of Western population.

show abstract

Short Term Outcomes of Low Dose Liraglutide in Obese Non Diabetic Indian Subjects-A Real World Experience

Cited by 2 publications

References 0 publications

Liraglutide – Indian experience

Liraglutide – Indian experience

First Fabulous Fifty – An Initial Experience of Dulaglutide from a Tertiary Care Centre in Eastern India

Contact Info

Product

Resources

About